Health Blueprint

Back to Longevity News

News summary

Efferon raises €4.3M to expand sepsis treatment technology into new markets

Source: Tech.eu • Published: 10 Nov 2026, 11:29

Summarized by Masters of Longevity from Tech.eu.

Efferon secured €4.3M to widen commercial reach and clinical evidence for hemoadsorption devices.

Efferon raises €4.3M to expand sepsis treatment technology into new markets
Key Takeaways
  • Efferon raised €4.3M to expand its device commercial footprint.
  • Funding is to support regulatory work and clinical evidence.
  • Real‑world data collection was planned in India and Latin America.
Read the full article at Tech.eu ↗

Continue exploring

Recommended MoL Picks

MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?